Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases.
- Patients undergoing secondary surgery had an overall survival of 51.0 months compared to 24.0 months for those with initial treatment alone.
- No difference in postoperative complications was observed between initial and secondary procedures.
Consider secondary surgery for well-selected patients to potentially enhance outcomes after recurrence.
- Patients undergoing secondary treatment had similar survival to those receiving initial surgery (27.0 months vs. 24.0 months).
Journal Article by Oppat KM, Bennett FJ (…) Concors SJ et 17 al. in Ann Surg Oncol
© 2026. Society of Surgical Oncology.